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a  b  s  t  r  a  c  t
Since  the  introduction  of the  meningococcal  C conjugate  (MCC)  vaccine  in  the  pediatric  population  in
1999,  numerous  clinical  studies  have  conﬁrmed  the  immunogenicity  and  safety  of the NeisVac-C® vac-
cine,  and  several  have  observed  a  strong  immune  response  after  a single  priming  dose,  which  could
be  successfully  boosted.  Maximizing  protection  of infants  with  as  few  vaccine  doses  as  possible  would
increase  the  general  acceptability  of the  immunization  strategies  and  support  broader  coverage  without
increasing  vaccination  costs.
This was  a  randomized  feasibility  study  of a  single  priming  NeisVac-C® vaccine  dose  administered
at  4 or  6  months  of age, compared  to the  currently  licensed  two  dose  priming  at 2 and  4  months  of
age,  followed  by a booster  vaccination  at 12–13  months  of  age.  High  seroprotection  rates  and  serum
bactericidal  antibody  (rSBA)  titers  were  observed  in  all study  groups,  whether  a single  or two  dose  priming
vaccination  was  administered,  at all  time  points  investigated:  one  month  after  the  priming  vaccination(s)
(>99%  of subjects  rSBA ≥ 8),  prior  to booster  vaccination  (>65%  of  subjects  with  rSBA  ≥ 8,  with the  lowest
titers  and  GMTs  seen  in  the  two dose  priming  group),  as  well  as  after booster  vaccination  administration
(99%  with  rSBA  ≥  128  in all three  study  groups,  with  the  highest  GMT  of  2472  seen  in  the  4  month  single
dose  group).  This  study  conﬁrmed  trends  seen  in previous  reports  that  a single-dose  priming  vaccination
at  4 or  6 months  of  age  can  be  considered  a valuable  alternative  to the  currently  licensed  two-dose
priming  vaccination  schedule.
 201©
. Introduction
Meningococcal serogroup C conjugate (MCC) vaccines were
uccessfully introduced as part of immunization campaigns in sev-
ral hyperendemic and epidemic regions during the 1999–2001
utbreak periods [1,2]. In the UK, the MCC  vaccination was
ncorporated into the routine infant immunization schedule and
as offered to under-18 year olds in a catch-up campaign (later
xtended to <25 year olds). The ﬁndings of this program suggest
hat it had a strong impact on the overall reduction in disease
Abbreviations: AE, adverse event; CI, conﬁdence interval; GCP, good clinical
ractice; GMT, geometric mean titer; ICH, International Conference on Harmoniza-
ion; IU, international unit; MCC, meningococcal C conjugate vaccine; rSBA, serum
actericidal activity (using rabbit complement); TT, tetanus toxoid; WHO, World
ealth Organization.
∗ Corresponding author. Tel.: +43 1 20 100.
E-mail address: Hartmut Ehrlich@baxter.com (H.J. Ehrlich).
264-410X © 2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2013.04.070
Open access under CC BY-NC-ND 3 The Authors. Published by Elsevier Ltd. 
incidence and attributable deaths in the targeted age groups as
well as in the prevalence of nasopharyngeal serogroup C meningo-
coccal carriage rates, providing a basis for indirect protection (herd
immunity) [2].
In the absence of controlled efﬁcacy trials, various national vac-
cination schedules were adopted considering the speciﬁc regional
epidemiological situation (such as endemicity and risk of meningo-
coccal disease during the ﬁrst year of life) as well as practical
and economic factors (number of overall doses available and cost-
effectiveness analyses) [3].
As children aged <2 years belong to one of the two age groups
with the highest reported incidence of meningococcal disease (the
other being 15–24 years old), the optimal protection of infants and
young children is under continuous evaluation [4]. Originally, in
order to ensure an adequate immune response, the primary vac-
cination schedule for MCC  vaccines in infants comprised three
doses. However, multiple doses in early infancy have been shown
to provide little if any additional beneﬁt compared to a reduced
Open access under CC BY-NC-ND license. primary vaccination schedule [5]. Further clinical trials provided
evidence that the infant primary schedule could be decreased to
two doses [6,7] and some with a MCC  vaccine using tetanus tox-
oid carrier protein (NeisVac-C®, Baxter Bioscience, Vienna, Austria)
license. 
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To assess noninferiority, point estimates and two-sided 90%
conﬁdence intervals (corresponding to one-sided 95% conﬁdence
intervals) of the differences between group response rates were612 E.-M. Poellabauer et al. /
uggested that high seroprotective titers could be induced with
 single vaccine priming dose. The ﬁrst such study was a pre-
icensure study in the UK, carried out in 1999, which found
eroprotective titers (rSBA ≥ 8) of 100.0% in infants vaccinated at
 months of age [8,9]. Two later studies in infants showed sero-
rotective antibody levels in 98.4% [6] and 97% [10] of subjects
dministered a single priming dose at 2 months of age, suggesting
hat single-dose priming strategies should be further investigated.
ecently, Findlow et al. [11] reported high seroprotective titers
chieved with a single priming dose of either MCC-TT or MCC-
RM197 vaccines administered at 3 months of age. Seroprotection
ates observed one month after a single priming dose with the
CC-TT vaccine (NeisVac-C®) were higher (100.0%) compared to
he MCC-CRM197 vaccine (95.5%); a comparison to the currently
icensed two-dose priming schedule had not yet been performed.
The aim of the present clinical study was to assess the feasibility
f a single priming dose of NeisVac-C® compared to the two-
ose priming as well as to evaluate the magnitude of the booster
esponse following a single dose or two-dose priming. Further-
ore, the safety of the different vaccine schedules was investigated.
. Materials and methods
.1. Study design and participants
A multicenter, randomized, open label study was conducted in
nfants aged 8–11 weeks at twenty-four study sites in Spain and
oland. Healthy subjects who had not received any recent vaccina-
ion or other investigational drugs were randomly assigned to one
f three treatment groups to receive either a single dose of 0.5 mL  of
eisVac-C® vaccine at 4 months (Group 1) or 6 months (Group 2) of
ge, respectively, or two doses of the vaccine at 2 and 4 months of
ge (Group 3). All subjects received a booster vaccination between
2 and 13 months of age.
Concomitant vaccinations of 0.5 mL  Infanrix® hexa and 0.5 mL
revenar 13® were administered to all subjects at 2, 4 and 6 months
f age, with booster vaccinations between 12 and 13 months of age.
The study was designed to analyze the number and proportion
f subjects with seroprotective antibody titers presented for three
elected time points (co-primary end points): one month after the
rimary vaccination, prior to the administration of the booster
accination and one month after the booster vaccination. The
on-inferiority margin was set to 10% and 5%, for ﬁst two and
he third time points, respectively. The proportion of subjects
chieving seroprotection was assumed to be 95% one month after
he primary vaccination; 55% prior to the booster; and 99% one
onth after the booster dose. These three criteria for the co-
rimary endpoints had to be met  simultaneously. The independent
ndpoints could be assumed to be positively correlated; therefore
he overall power to meet all three criteria was greater than 80%.
or 300 evaluable subjects per group (assuming a dropout rate of
%) an overall number of 948 subjects (316 subjects per group)
ere to be enrolled in the study.
All vaccines in this study were given by intramuscular injection
nto the anterolateral thigh (musculus vastus lateralis).
The study was performed according to ICH-GCP guidelines and
he Declaration of Helsinki [12,13]. Approvals by the responsible
thics committees (in Poland: Biothics Committee in Wroclaw,
nd in Spain: Generalitat Valenciana), a ClinicalTrials.gov number
NCT01218451) and written parental/legal guardian informed con-
ent were obtained..2. Study vaccine
NeisVac-C® (Baxter BioSience, Vienna, Austria, batch number:
N914235X1) is a licensed conjugate vaccine comprised of thee 31 (2013) 3611– 3616
de-O-acetylated group C meningococcal polysaccharide coupled to
tetanus toxoid (MCC-TT). Each 0.5 mL  dose contains: N. meningi-
tidis group C (strain C11) polysaccharide (de-O-acetylated) 10 g,
conjugated to tetanus toxoid 10–20 g, adsorbed on aluminum
hydroxide, hydrated 0.5 mg  Al3+, and the excipients sodium chlo-
ride and water for injections.
2.3. Concomitant vaccinations
Prevenar 13® (Pﬁzer Inc., batch numbers: E29359 and E47034)
contains the capsular saccharides of the capsular antigens of Strep-
tococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,
19F, and 23F, individually linked to non-toxic diphtheria CRM197
protein.
Infanrix hexa® (GlaxoSmithKline Biologicals, batch numbers:
A21CA658C and A21CB009A) contains not less than 30 IU (25 Lf U)
of Diphtheria toxoid,1 tetanus toxoid1 ≥ 40 IU, Bordetella pertussis
antigens (Pertussis toxoid1, Filamentous haemagglutinin1, Per-
tactin1) 25, 25, 8 g, Hepatitis B surface antigen2 10 g, Poliovirus
(inactivated) type 1, 2 and 3, 40, 8, 32 DU Haemophilus inﬂuen-
zae Type b polysaccharide 10 g (polyribosylribitol phosphate) 2
conjugated to tetanus toxoid as carrier protein 20–40 g.
2.4. Immunogenicity assessments
Blood samples for the assessment of immune response were
drawn immediately prior to the priming and booster vaccination(s)
as well as one month after priming and booster vaccination(s) with
NeisVac-C®, and at the ﬁnal study visit.
To evaluate the antibody response to the vaccine, meningococ-
cal serogroup C11 rSBA was assessed using rabbit complement, as
described previously [14].
The non-inferiority of seroprotection rates (rSBA titers ≥ 8) fol-
lowing a single priming dose (at either 4 or 6 months of age) was
investigated as compared to a two-dose priming (at 2 and 4 months
of age) one month after the primary vaccination (rSBA titers ≥ 8),
prior to the administration of the booster dose (rSBA titers ≥ 8), and
one month after the booster vaccination (rSBA titers ≥ 128).
2.5. Safety assessments
Safety was assessed by the frequency and severity of local and
systemic reactions with onset 3 days after each vaccination and of
adverse events (AEs) observed during the entire follow up period.
The subject’s parents/legal guardians received a subject diary for
documentation of AEs. These diaries were returned to the investi-
gator at follow-up visits. Investigators recorded any AEs reported
during study visits. The parents/legal guardian(s) were asked to
monitor and register in the Subject Diary their child’s rectal body
temperature for 72 h after vaccination. To optimize the compa-
rability of the documented body temperatures, all parents/legal
guardian(s) were provided with a digital thermometer. If fever
(deﬁned as a rectal body temperature ≥ 38.0 ◦C) occurred, body
temperature was  to be measured every 4–8 h until it returned to
normal. Fever was  rated according to the WHO  guidelines [15].
2.6. Statistical methods1 Adsorbed on Al(OH)3 (0.5 mg Al).
2 Adsorbed on AlPO4 (0.32 mg Al).
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omputed by inverting the Miettinen–Nurminen test for the dif-
erence between two independent proportions [16].
The lower limit of detection for the assay quantifying the rSBA
iter values is 0.04. Data below the detection limit was  replaced by
he detection limit.
The geometric means and 95% CIs of rSBA titers measured at the
hree analysis timepoints were computed, assuming a lognormal
istribution. rSBA titer values were logarithmically transformed;
eans and 95% CIs were then computed by vaccination group
nd back-transformed by exponentiation to the original scale. For
ll three endpoints, pairwise comparisons were performed, com-
uting the one-sided 95% conﬁdence intervals of the differences
etween response rates by inverting the Miettinen–Nurminen test
or the difference between two independent proportions [16]. The
wo pairwise comparisons were performed in a hierarchical man-
er. This closed testing procedure preserved the type I error rate;
herefore, no adjustment for multiplicity was needed.
The geometric means and 95% CIs of fold increases from baseline
f rSBA titers measured at the three analysis timepoints were cal-
ulated as follows: rSBA titers were logarithmically transformed,
hen changes from baseline were computed for each subject. Mean
hanges from baseline and 95% CIs were estimated by vaccination
roup and then back-transformed by exponentiation to the original
cale.
For safety analyses, incidence rates and their exact 95% CIs
Clopper–Pearson) were calculated for each group. For subjects in
he two dose group, AEs which occurred at least once (month 2 or
) were considered “after the primary vaccination.”
. Results
.1. Demography
A total of 979 subjects were screened and 956 male and female
ubjects were randomized into one of three study groups (at 20
olish and Spanish study sites) (Table 1).
.2. Immunogenicity analysis
.2.1. Primary vaccination
The number and proportion of subjects with seroprotective anti-
ody titers (rSBA titers ≥ 8) one month after completion of the
rimary vaccination was very similar and over 99.0% in all three
roups (Table 2). The difference between the 6-month single dose
roup and the two dose group was −0.4 and the difference between
he 4-month single dose group and the two dose group was  0, indi-
ating non-inferiority of the one-dose priming regimens compared
o the two-dose regimen (Table 2).
At one month after the primary vaccination, the two dose group
howed the highest rSBA titers, with 624.1 geometric mean titer
GMT), compared to 372.1 in the 4-month single dose group, and
01.8 in the 6-month single dose group. The geometric fold increase
rom baseline was also signiﬁcantly higher in the two dose group
150.7) compared to the 4 month (85.9) and the 6 month (97.3)
ingle dose groups (Table 3).
.2.2. Pre-booster evaluation
Prior to the booster dose, 78.0% and 90.7% of subjects in the
- and 6-month single dose groups had seroprotective antibody
iters, respectively, compared to 67.8% of those in the two-dose
roup (Table 2). The differences between the single dose groups (at and at 6 months, respectively) and the two dose group were 10.3%
95% CI: 3.8–16.7) and 22.9% (95% CI: 17.2–28.7), indicating non-
nferiority of both one-dose regimens compared to the two-dose
egimen (the non-inferiority margin was set to 10%).e 31 (2013) 3611– 3616 3613
Prior to administration of the booster vaccination, the 6-month
single dose group showed the highest rSBA titers, with 84.8 GMT,
compared to 38.5 in the 4-month single dose group, and 29.5 in
the two dose group (Table 3). The geometric fold increase from
baseline was also signiﬁcantly higher in the 6-month (20.2; 95% CI:
16.9–24.1) compared to the 4-month (8.8; 95% CI: 7.4–10.6) dose
group and the two  dose group (7.1; 95% CI: 5.8–8.7).
3.2.3. Post booster evaluation
One month after the booster dose, approximately 99.0% of
subjects in all three dose groups showed rSBA titers ≥ 128. The dif-
ference between the 6-month single dose and the two dose group
was: 0.0 (95% CI: −1.3 to 1.5) and the difference between the 4-
month single dose group and the two  dose group was −0.7 (95%
CI: −2.5 to 0.8), indicating non-inferiority of the one-dose regimen
compared to the two-dose priming regimen (Table 2).
At one month after the booster vaccination, the 4-month single
dose group showed the highest rSBA titers, with 2472.1 GMT,  com-
pared to 1874.8 in the 6-month single dose group, and 1538.0 in
the two dose group (Table 3). The geometric fold increase from
baseline was  also substantially higher in the 4-month (569.0;
95% CI: 501.3–645.9) compared to the 6-month (446.3; 95% CI:
395.2–504.1) single dose group and the two  dose (372.6; 95% CI:
333.0–417.0).
3.3. Safety analysis
A very similar safety proﬁle was observed whether a single-dose
or a two-dose primary vaccination schedule was administered.
Of the 945 subjects included in the safety data set, 92 sub-
jects reported SAEs after vaccination with NeisVac-C®, Prevenar
13® and Infanrix hexa® (an additional 30 subjects reported
SAEs after randomization and possible vaccination with Preve-
nar 13® or Infanrix hexa®, but prior to NeisVac-C® vaccination)
of which 3/92 in two  subjects were considered possibly related
to NeisVac-C® vaccination: a case of pyrexia (39.2 ◦C, sus-
pected bacteraemia) occurring one day after vaccination in a
4-month old female and a case of fever and diarrhea occur-
ring 3 days after booster vaccination in a 13-month-old male.
Infanrix hexa®, and Prevenar 13® were administered con-
comitantly in both subjects. No deaths occurred during the
study.
A total of 739 subjects reported non-serious injection site reac-
tions and 842 reported treatment-related non-serious systemic
adverse events during the study period. The number of subjects
with injection site reactions and of those with systemic reactions
within 3 days after concomitant vaccination of NeisVac-C®, Infan-
rix hexa®, and Prevenar 13® was consistent between the three
study groups at approximately 50%, for injection site reactions,
and between 45% and 65% for systemic reactions (with gener-
ally lower rates after the booster vaccinations compared to the
primary vaccination regimen). Most were considered mild or mod-
erate.
The most common queried injection site reactions were ery-
thema, induration, injection site pain, and swelling, and the
most common queried systemic reactions were crying, decreased
appetite, irritability, pyrexia, sleep disorder and somnolence
(Table 4). Again, the proportions of subjects with queried injection
site and systemic reactions were similar between the three study
groups.
In the ﬁrst 3 days after vaccination, the number of subjects who
experienced fever was similar across the three study groups, and in
the majority of subjects, it lasted less than 24 h. Rates of fever were,
as expected, somewhat higher after the primary vaccinations than
after the booster vaccination at 12–13 months of age.
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Table 1
Demography of the subject population at baseline.
Parameter Category Group 1N = 318n (%) Group 2N = 312n (%) Group 3N = 315n (%) TotalN = 945n (%)
Gender Male 173 (54.4) 167 (53.5) 157 (49.8) 497 (52.6)
Female 145 (45.6) 145 (46.5) 158 (50.2) 448 (47.4)
Age  (weeks) Mean 7.7 7.6 7.7 7.7
Median 8.0 7.0 8.0 8.0
Range 6–11 6–11 6–11 6–11
Table 2
Number and proportion of subjects with seroprotective rSBA titers.
Age (months) at vaccination
4 months 6 months 2 and 4 months
n/N (%) 90% CIa n/N (%) 90% CIa n/N (%) 90%CIa
One month after the administration of the primary vaccination [rSBA titers ≥ 8]
270/271 (99.6) 98.3–100.0 263/265 (99.2) 97.6–99.9 249/250 (99.6) 98.1–100.0
Prior  to the administration of the booster vaccination [rSBA titers ≥ 8]
206/264 (78.0) 73.4–82.2 234/258 (90.7) 87.2–93.5 166/245 (67.8) 62.5–72.7
One  month after the administration of the booster vaccination [rSBA titers ≥ 128]
261/264 (98.9) 97.1–99.7 257/258 (99.6) 98.2–100.0 242/243 (99.6) 98.1–100.0
a Clopper–Pearson CI.
Table 3
Magnitude of rSBA GMT.
Age (months) at vaccination
4 months 6 months 2 and 4 months
GMT 95% CI a GMT  fold increaseb GMT  95% CI a GMT fold increaseb GMT 95% CI a GMT  fold increaseb
One month after the administration of the primary vaccination
372.1 339.4–408.1 85.9 401.8 361.6–446.5 97.3 624.1 568.2–685.5 150.7
Prior  to the administration of the booster vaccination
38.5 32.3–45.9 8.8 84.8 71.9–100.1 20.2 29.5 24.4–35.7 7.1
One  month after the administration of the booster vaccination
2472.1 2226.3–2745.0 569.0 1874.8 1684.4–2086.6 446.3 1538.0 1381.1–1712.6 372.6
a CIs based on the t-distribution applied for log-transformed data (then back-computed).
b Fold increase from baseline.
Table 4
Proportion of subjects reporting speciﬁcally queried symptoms of non-serious local and systemic reactions following NeisVacC vaccination (administered concomitantly
with  Prevenar® 13 and Infanrix Hexa® at all timepoints).
Analysis time point Adverse event Single 4-month dose
group, N = 318
% (95% CI)
Single 6-month dose
group, N = 312
% (95% CI)
Two  dose (2 and 4
months) group, N = 315
%  (95% CI)
Primary vaccination
Local reactions Injection site erythema 34.6 (29.4; 40.1) 33.7 (28.4; 39.2) 41.0 (35.5; 46.6)
Injection site induration 35.2 (30.0; 40.7) 39.4 (34.0; 45.1) 47.9 (42.3; 53.6)
Injection site swelling 17.3 (13.3; 21.9) 23.7 (19.1; 28.8) 24.8 (20.1; 29.9)
Systemic reactions Pyrexia 34.9 (29.7; 40.4) 26.3 (21.5; 31.5) 42.2 (36.7; 47.9)
Hyperhydrosis 4.1 (2.2; 6.9) 3.5 (1.8; 6.2) 7.6 (4.9; 11.1)
Irritability 28.0 (23.1; 33.3) 29.5 (24.5; 34.9) 39.0 (33.6; 44.7)
Sleep disorder 15.1 (11.3; 19.5) 13.5 (9.9; 17.8) 23.8 (19.2; 28.9)
Somnolence 14.2 (10.5; 18.5) 12.8 (9.3; 17.0) 35.6 (30.3; 41.1)
Vomiting 1.6 (0.5; 3.6) 1.9 (0.7; 4.1) 2.5 (1.1; 4.9)
Booster vaccination
Local reactions Injection site erythema 28.3 (23.4; 33.6) 36.9 (31.5; 42.5) 32.7 (27.5; 38.2)
Injection site induration 27.7 (22.8; 32.9) 34.9 (29.7; 40.5) 33.3 (28.1; 38.8)
Injection site swelling 20.8 (16.4; 25.6) 24.0 (19.4; 29.2) 24.4 (19.8; 29.6)
Systemic reactions Pyrexia 20.8 (16.4; 25.6) 25.3 (20.6; 30.5) 18.1 (14.0; 22.8)
Hyperhydrosis 3.1 (1.5; 5.7) 3.2 (1.5; 5.8) 4.8 (2.7; 7.7)
Irritability 25.5 (20.8; 30.6) 29.2 (24.2; 34.6) 23.8 (19.2; 28.9)
Sleep disorder 11.0 (7.8; 15.0) 13.1 (9.6; 17.4) 12.7 (9.2; 16.9)
Somnolence 7.9 (5.2; 11.4) 13.1 (9.6; 17.4) 6.7 (4.2; 10.0)
Vomiting 1.3 (0.3; 3.2) 1.9 (0.7; 4.1) 0.3 (0.0; 1.8)
 Vaccin
4
p
c
g
p
m
l
g
o
t
r
n
t
p
r
o
t
4
u
a
e
G
p
t
m
b
I
y
r
s
a
a
r
p
l
r
v
c
t
i
w
d
t
s
p
r
a
o
v
i
m
s
b
b
d
w
s
c
wE.-M. Poellabauer et al. /
. Discussion
With new vaccines continually being added to many national
ediatric vaccination schedules, the reduction of vaccination doses
an increase the general acceptability of the immunization strate-
ies among targeted parental communities. The need to maximize
rotection of children and especially infants against Neisseria
eningitidis serogroup C with as few vaccine doses as possible has
ed to additional clinical studies comparing the safety and immuno-
enicity proﬁles of different vaccination schedules.
The data in the present study showed the proven tolerability
f the NeisVac-C® vaccine, as seen previously [8,2,17], in addi-
ion to conﬁrming observations that the priming series could be
educed from two doses to one dose, and that this reduction does
ot adversely affect seroprotection rates or the magnitude of rSBA
iters [10,11].
At one month after the priming vaccination regimen, high sero-
rotection rates were observed in all study groups (>99% of subjects
SBA ≥ 8). The two-dose priming schedule group (at 2 and 4 months
f age) showed the highest antibody levels (GMT of 624) compared
o the two single dose study groups (GMTs of 372 and 401 for the
 month and 6 month dose groups, respectively), which was  not
nexpected, as the two dose priming group had received the largest
mount of antigen [6]. Prior to the booster vaccination, the high-
st seroprotection rates and functional antibody titers (90.7%; rSBA
MT: 84.8) were observed in the 6-month single-dose group, com-
ared to 67.8% (29.5 GMT) and 78.0% (38.5 GMT), respectively, in
he two-dose and 4-month single dose groups. This difference was
ost likely due to the shorter time interval between priming and
ooster vaccinations for subjects in the 6-month single-dose group.
n addition, these children were older at the time of priming; at this
oung age, a difference of 2 months may  strongly affect immune
esponse. It has been reported that conjugated vaccines induced
igniﬁcantly lower immunological responses at 2 or 3 months of
ge when compared to 6 month vaccination age [18]. Furthermore,
 single dose MCC-TT vaccine administered at 3 months of age
esulted in a signiﬁcant titer decline (28% of subjects had rSBA ≥ 8)
rior to booster at 12 months, compared to the seroprotective titer
evels observed pre-booster in the present study (78.0% and 90.7%,
espectively, in the 4- and 6-month single dose groups) [11].
In early infancy, the immune response to priming with MCC
accines is determined by genetic factors such as sizes of germinal
enters with smaller or larger memory B cell pools, and their ability
o produce lower or higher antibody levels after priming, depend-
ng on immune system maturity [19,20]. However, in countries
hich experience a high incidence of serogroup C meningococcal
isease in early infancy, a late start regimen can pose a risk of infec-
ion; therefore, national recommendations on vaccination posology
hould be considered.
The 4-month single-dose group showed signiﬁcantly higher
ost-booster antibody titers (GMTs of 2472.1) compared to the
emaining groups. Subjects who were primed with the single dose
t 6 months of age showed a slightly lower booster response (GMTs
f 1874.8), probably due to higher rSBA levels at the time of booster
accination (as a result of primary vaccination with the shortest
nterval prior to booster) which may  have interfered with the for-
ation of the booster response.
Although the magnitude of the rSBA GMT  between the 4-month
ingle-dose group and the two-dose group were similar at pre-
ooster, the immune reactions diverged substantially following
ooster. The lower rSBA GMTs observed post- booster in the two-
ose group vaccinated at 2 and 4 months of age seems consistent
ith the trend noted by Richmond et al. [21] and Borrow et al. [6]
howing that the quantity of antigen administered during priming
orrelates positively with post-primary rSBA levels but negatively
ith the magnitude of the booster response. In addition, thee 31 (2013) 3611– 3616 3615
so-called protein carrier-induced epitope suppression dedicated to
the tetanus toxoid (TT) component (contained in both NeisVac-C®
and Infanrix hexa®) may  also induce a dose-dependent suppression
of the antigen response. It is well known that a low-dose TT priming
induces an exaggerated reaction to polysaccharides conjugated to
the carrier protein, while larger dose TT priming can suppress the
antigen response [22,23]. The discrete level of TT needed to cause
an inverse correlation with an antigen antibody response is, how-
ever, unknown; therefore, a potential relationship between higher
TT levels and a reduced booster response cannot be conﬁrmed from
the results of this study.
Although the post-booster results illustrate a strong immuno-
logical response in all study groups, extended duration of
protection may require particularly high rSBA levels as the actual
magnitude of the booster response appears to determine persis-
tence [24].
The results of the present study demonstrate that the single-
dose priming vaccination of NeisVac-C® at either 4 or 6 months of
age is non-inferior to administration of a two-dose priming sched-
ule at 2 and 4 months of age with respect to immunogenicity against
serogroup C meningococci. Thus, a single-dose priming vaccination
at 4 or 6 months of age followed by a booster vaccination in the
beginning of the second year of life can be considered a valuable
alternative to the currently licensed two-dose priming vaccination
schedule.
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